Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today
Aura AI Summary
Key Stats
- $13.24BMarket Cap
- HealthSector
- -18.03%3M Drawdown
- $14.80BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 59 daysTypical Hold Time
BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $13.24B, with an enterprise value of $14.80B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $38.62 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -18.03%, reflecting recent price volatility. On average, investors hold BridgeBio Pharma Inc for approximately 59 days, indicating typical investor behavior on the platform.
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Most Recent News
Tesla's robotaxi fleet shrinks amid safety concerns; SpaceX IPO filing hints at major equity moves.
Tesla has reduced its robotaxi fleet to about 20 vehicles despite expanding the Austin service area, raising safety concerns from former engineers. Meanwhile, SpaceX updated its IPO filing, indicating a lock-in period for Musk's shares and potential ...

AI boom drives strong earnings beats, policy debates, and major tech moves worldwide
Recent financial reports show strong earnings beats driven by surging demand for artificial intelligence (AI) technologies, with companies like ServiceTitan, Palo Alto Networks, and CrowdStrike exceeding revenue and earnings estimates. Policymakers i...

Foundayo leads to significant weight loss in menopausal women, including those with type 2 diabetes, in clinical trials.
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
